Large lymphadenopathies complicating the abacavir hypersensitivity reaction [4]

AIDS

Volumn 21, Issue 16, 2007, Pages 2254-2256

  García, Jesús Troya ^a   González, Pablo Rivas ^a   Hernández Mora, Miguel Górgolas ^a   Novoa, Sonia Rodríguez ^a   Quintana, Francisco Blanco ^a   Lahoz, Juan González ^a   Vázquez, Vincent Soriano ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CORTICOSTEROID; HLA B7 ANTIGEN; INFUSION FLUID; LAMIVUDINE; RITONAVIR;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LETTER; LYMPHADENOPATHY; MALAISE; MALE; MULTIPLE ORGAN FAILURE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RNA ANALYSIS; SPAIN; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 37349114850     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f08c47     Document Type: Letter

References (9)

1. Hervey P, Perry C. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 2000; 60:447-479.
2. Stekler J, Maenza J, Stevens C, Holte S, Malhotra U, McElrath M, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 2006; 20:1269-1274.
3. Habermann T, Steensma D. Lymphadenopathy. Mayo Clin Proc 2000; 75:723-732.
4. Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin 2006; 24:549-570.
5. Chui C, Brumme Z, Brumme C, Yip B, Phillips E, Montaner J, et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007; 44:1503-1508.
6. Zabrina L, Brumme P, Harrigan R. The impact of human genetic variation on HIV disease in the era of HAART. AIDS Rev 2006; 8:78-87.
7. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59:591-593.
8. Mallal S, Nolan D, Witt C, Masel G, Martin A, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
9. Rodriguez-Novoa S, Garcia-Gasco P, Blanco F, Gonzalez-Pardo G, Castellares C, Moreno V, et al. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retroviruses 2007. In press